Recently, an investor asked Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) . The seventh batch of centralized purchase has been released. Does the company’s relevant products participate in the registration? Will ibandronate injection with strong growth this year be affected by centralized mining? On February 22, Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) issued a reply to the above questions.
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) replied that the seventh batch of centralized purchase is expected to be implemented from June to July this year. For the stock varieties of ibandronate injection and caffeine citrate injection before centralized purchase, the company will continue to strengthen market promotion and maintain good sales performance. It is expected that it will not be affected by centralized purchase in the first half of the year. At present, the company is carrying out various demonstration work to participate in the selection of centralized procurement bidding, so as to ensure the scientific selection. If the centralized purchase is successfully selected, it will have a certain impact at the initial stage of the implementation of centralized purchase. However, with the expansion of terminal coverage in the selected provinces and the academic promotion of hospital sales, it will quickly enter the normal expectation of sales. In the whole centralized purchase cycle, it is expected that it will not have a great impact on the overall sales scale.
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) in its 2021 semi annual report, it is mentioned that caffeine citrate injection and ibandronate sodium injection are the main varieties of the company. Among them, caffeine citrate injection, a child drug, is the first imitation of a listed drug, ranking first in market share in 2020. The anti-tumor drug ibandronate sodium injection has rich specifications, and its market share ranked second in 2020.
Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) believes that with the development of centralized procurement, the quotations of various manufacturers have become relatively calm and objective, while the other three “barefoot” products involved in this centralized procurement, memantine hydrochloride sustained-release capsule, paricalcitol injection and propofol tenofovir fumarate tablets, the company is also actively bidding to ensure the successful selection and bring net increment to the company, To some extent, it will offset the short-term impact of the price reduction of ibandronate and caffeine citrate injection. In the long run, the impact on the overall performance is relatively controllable.
